Immunovant 

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31
Revenue
$0
$1,500
$0
Gross Profit
-80
1,436
-58
EBITDA
-94,201
-80,815
-61,495
EBIT
-94,281
-80,879
-61,553
Net Income
-87,150
-75,319
-51,418
Net Change In Cash
0
1,500
0
Free Cash Flow
-76,381
-59,849
-47,229
Cash
560,005
635,365
690,937
Basic Shares
146,085
145,355
144,523

Annual Financials

Values in thousands 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Revenue
$0
$0
$0
$0
Gross Profit
-231
-1,324
-1,232
-998
EBITDA
-269,978
-209,627
-155,582
-106,791
EBIT
-270,209
-210,951
-156,814
-107,789
Net Income
-259,336
-210,960
-156,730
-107,431
Net Change In Cash
0
0
0
0
Cost of Revenue
-117,505
93,763
299,575
Free Cash Flow
-214,587
-188,390
-106,366
-83,537
Cash
635,365
376,532
493,817
400,146
Basic Shares
138,100
123,075
109,679
87,756

Earnings Calls

Quarter EPS
2024-09-30
-$0.74
2024-06-30
-$0.60
2024-03-31
-$0.52
2023-12-31
-$0.36